Nephroprotective effect of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and chronic kidney disease
- 13 June 2026
- journal article
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (5)
Abstract
Aim. To evaluate the changes of renal function during treatment with sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with atrial fibrillation (AF) and chronic kidney disease (CKD). Material and methods. A total of 100 patients with AF and stage 3-4 CKD were included. Serum creatinine levels, creatinine clearance (CrCl) according to the Cockcroft-Gault equation, and glomerular filtration rate (GFR) using the CKD-EPI equation were assessed. A decrease in GFR ≥20%, a doubling of creatinine levels, and the development of acute kidney injury (AKI) were analyzed. Results. After 18 months, the GFR in the study group averaged 10,1 (95% confidence interval: 3,6; 16,7) ml/min/1,73 m 2 higher than in the control group. In patients with stage C3B CKD, the GFR level increased by 4,3±10,5 ml/min/1,73 m 2 from baseline. Patients taking SGLT-2 inhibitors had an increased risk of progression from stage C3B CKD to stage C3A: odds ratio (OR) =0,53; 95% confidence interval: 0,42; 0,67. Differences in kidney function were observed only with renin-angiotensin system inhibitors. No doubling of creatinine levels or development of acute kidney injury was observed. There were no differences between groups in the incidence of a decrease in GFR ≥20%. Conclusion. The renoprotective effect of SGLT-2 inhibitors is maintained in patients with combined AF and CKD, especially in patients with CKD stage C3B.Keywords
This publication has 19 references indexed in Scilit:
- Renoprotective potential of concomittant medications with SGLT2 inhibitors and renin-angiotensin system inhibitors in diabetic nephropathy without albuminuria: a retrospective cohort studyScientific Reports, 2023
- A real-world study on SGLT2 inhibitors and diabetic kidney disease progressionClinical Kidney Journal, 2022
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney DiseaseKidney International, 2021
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2020
- Pathophysiology of atrial fibrillation and chronic kidney diseaseCardiovascular Research, 2020
- A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseasesKidney International, 2019
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysisThe Lancet Diabetes & Endocrinology, 2019
- Mixed‐effects models for slope‐based endpoints in clinical trials of chronic kidney diseaseStatistics in Medicine, 2019
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019
- Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysisAmerican Journal of Kidney Diseases, 2016